EHC earnings analysis
What we found in EHC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Encompass Health reported Q2 2026 revenue of $1.597 billion and diluted EPS of $1.55. Revenue increased approximately 0.4% sequentially and 9.4% year over year, while EPS declined 19.7% sequentially but rose 11.5% year over year. The provided filing extract contains no segment, cash-flow, margin, balance-sheet, or quantitative guidance details, and reports no material changes to the prior 10-K risk factors.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue continued to grow
- Revenue was $1.597 billion, up from $1.59 billion in Q1 2026 and $1.46 billion in Q2 2025, representing approximately 0.4% sequential growth and 9.4% year-over-year growth.
- EPS up year over year
- Diluted EPS was $1.55, compared with $1.93 in Q1 2026 and $1.39 in Q2 2025. EPS declined approximately 19.7% sequentially but increased 11.5% year over year.
- Share repurchases remained active
- The company repurchased 704,246 shares during the quarter at an average price of $103.81 per share, supporting per-share value but using capital for buybacks.
- Repurchase authorization expanded
- On July 23, 2026, the board reset the aggregate common-stock repurchase authorization to $1.0 billion, up from the previously cited $500 million authorization.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No formal risk-factor update
- Item 1A states that there have been no material changes from the risk factors in the 2025 Form 10-K. The filing instead points investors to the MD&A's “Executive Overview—Key Challenges” discussion for updates.
- Expanded buyback capital commitment
- The board reset the repurchase authorization to $1.0 billion on July 23, 2026. Although discretionary, deploying capital at that scale could reduce liquidity available for debt reduction, acquisitions, or other corporate needs.
- Debt details not provided in extract
- The filing includes an indenture dated May 29, 2026, following the company's issuance of senior notes. The provided text does not disclose the outstanding debt balance, maturity profile, or covenant headroom, limiting assessment of leverage risk.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.55
What they said about what is next.
No quantitative outlook was included in the provided 10-Q text. The filing states that there were no material changes to the risk factors disclosed in the 2025 Form 10-K; outlook information may be in the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 1, 2026
- Encompass Health Corporation (EHC) reported strong Q1 2026 results, with net operating revenues increasing 9.0% year-over-year to $1.586 billion, surpassing estimates of $1.568 billion. Diluted EPS came in at $1.77,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EHC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever